Latest Ratios: P/E Ratio 0.5x · EV/EBITDA N/A · ROE 49.2%. (2025–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 |
|---|---|---|
| Market Cap | $103849 | — |
| Enterprise Value | $-746319 | — |
| P/E Ratio → | 0.53 | — |
| P/S Ratio | 0.02 | — |
| P/B Ratio | 0.29 | — |
| P/FCF | — | — |
| P/OCF | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 |
|---|---|---|
| EV / Revenue | — | — |
| EV / EBITDA | — | — |
| EV / EBIT | — | — |
| EV / FCF | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 |
|---|---|---|
| Gross Margin | 52.7% | 52.7% |
| Operating Margin | -21.2% | -21.2% |
| Net Profit Margin | 11.5% | 11.5% |
| Metric | TTM | FY 2025 |
|---|---|---|
| ROE | 49.2% | 49.2% |
| ROA | 8.3% | 8.3% |
| ROIC | — | — |
| ROCE | -41.6% | -41.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 |
|---|---|---|
| Debt / Equity | 1.22 | 1.22 |
| Debt / EBITDA | — | — |
| Net Debt / Equity | — | -0.55 |
| Net Debt / EBITDA | — | — |
| Debt / FCF | — | — |
| Interest Coverage | -3.48 | -3.48 |
Net cash position: cash ($3M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 |
|---|---|---|
| Current Ratio | 0.90 | 0.90 |
| Quick Ratio | 0.63 | 0.63 |
| Cash Ratio | 0.47 | 0.47 |
| Asset Turnover | — | 0.73 |
| Inventory Turnover | 2.02 | 2.02 |
| Days Sales Outstanding | — | 28.62 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 |
|---|---|---|
| Dividend Yield | 17.5% | — |
| Payout Ratio | — | — |
| Metric | TTM | FY 2025 |
|---|---|---|
| Earnings Yield | 100.0% | — |
| FCF Yield | — | — |
| Buyback Yield | 0.0% | — |
| Total Shareholder Yield | 17.5% | — |
| Shares Outstanding | — | $85M |
Insolvency and liquidity constraints
According to recent market data, MEHA trades at a P/S ratio of 0.02 and a P/B of 0.29, suggesting that investors are pricing the company as a distressed asset rather than a growth-oriented medical device manufacturer, likely due to the persistent operating losses and negative equity base.
The extremely low valuation multiples indicate that the market has largely discounted the company's future earnings potential, viewing the current revenue base as insufficient to support the existing cost structure. Investors should monitor whether these levels represent a deep-value opportunity or a rational reflection of the company's inability to achieve sustainable scale in the competitive Chinese medical distribution market.
Based on reported figures, MEHA's ROIC has trended into negative territory, reaching -75.1% in 2025Q4, which indicates that the company is currently destroying shareholder capital rather than compounding it through its manufacturing and distribution activities, a trend that warrants significant caution from long-term investors.
The collapse in return metrics suggests that the capital invested in manufacturing infrastructure and regulatory certifications is not generating adequate returns relative to the company's high fixed-cost base. This decay in efficiency appears structural, as the company struggles to align its operational output with the capital deployed to maintain its NMPA-certified product portfolio.
As reported in financial statements, MEHA's inventory turnover remains sluggish, with DIO figures frequently exceeding 200 days, highlighting a significant inefficiency in managing medical device stock levels that ties up critical liquidity and complicates the company's ability to respond to rapid shifts in provincial hospital demand.
The extended cash conversion cycle suggests that the company lacks leverage over its supply chain or is holding excessive inventory to ensure product availability for hospital tenders. This inefficiency exacerbates the company's liquidity constraints, as cash remains trapped in slow-moving inventory rather than being recycled into core operations.
According to recent quarterly filings, MEHA's quick ratio has fluctuated near 0.64, indicating that the company's liquid assets are insufficient to cover its immediate short-term obligations without relying on the liquidation of inventory, which may be difficult given the current market environment for medical disposables.
The thin liquidity buffer suggests that the company is highly vulnerable to any further contraction in revenue or unexpected spikes in operating expenses. Without a clear path to positive cash flow, the company appears to be operating with a limited runway, increasing the risk of a liquidity crisis that could necessitate dilutive financing.
Investors frequently misapply the P/E ratio to MEHA, which obscures the company's true financial health by ignoring the significant non-operating income and subsidies that artificially inflate net income figures while the core business continues to burn cash through persistent operating losses.
Because the company's net income is often decoupled from its operating performance, the P/E ratio provides a misleading picture of profitability. Analysts should instead focus on operating cash flow and gross margin stability to assess the underlying viability of the business model, as these metrics better reflect the company's ability to survive without non-core support.
Includes 30+ ratios · 1 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MEHA stock.
Functional Brands, Inc. Common Stock's current P/E ratio is 0.5x. This places it at the 50th percentile of its historical range.
Functional Brands, Inc. Common Stock's return on equity (ROE) is 49.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 49.2%.
Based on historical data, Functional Brands, Inc. Common Stock is trading at a P/E of 0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Functional Brands, Inc. Common Stock's current dividend yield is 17.49%.
Functional Brands, Inc. Common Stock has 52.7% gross margin and -21.2% operating margin.